Creative Medical Technology Holdings, In - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CELZ Nasdaq 2836 www.creativemedicaltechnology.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Creative Medical Technology Holdings, In

Creative Medical Technology Holdings Issues Mid-Year Update - Jul 1st, 2026 7:00 am
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds - Jun 30th, 2026 12:07 pm
These Three Stocks Fell More Than 10% Today To Hit 52-Week Lows -- What's Driving The Investor Skepticism? - Jun 26th, 2026 11:54 am
Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain - Jun 22nd, 2026 7:15 am
Creative Medical Technology opens nationwide burn-pit data registry - Jun 16th, 2026 1:49 pm
Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards - Jun 16th, 2026 7:00 am
Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies - Apr 28th, 2026 7:01 am
Analysts Expect Breakeven For Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Before Long - Apr 9th, 2026 4:56 am
Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline - Feb 10th, 2026 7:00 am
Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain - Jan 13th, 2026 7:15 am
Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative - Jan 6th, 2026 7:15 am
Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point - Dec 17th, 2025 7:15 am
Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201 - Dec 2nd, 2025 7:15 am
Bears are Losing Control Over Creative Medical Technology Holdings, Inc. (CELZ), Here's Why It's a 'Buy' Now - Nov 5th, 2025 7:55 am
Market Sentiment Around Loss-Making Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) - Oct 31st, 2025 4:39 am
Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits - Oct 30th, 2025 7:15 am
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds - Oct 29th, 2025 7:00 am
Creative Medical Technology Holdings Issues Letter to Shareholders - Oct 27th, 2025 6:15 am
Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs - Oct 7th, 2025 7:15 am
Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back Pain - Aug 13th, 2025 7:01 am